12 June 2020 - NICE has drawn up draft guidelines rejecting Sanofi's Cablivi (caplacizumab) for use alongside plasma exchange and immunosuppression for treating an acute episode of acquired thrombotic thrombocytopenic purpura.

Adding Cablivi could reduce the long-term complications of acquired thrombotic thrombocytopenic purpura and risk of death around the time of an acute episode.

However, NICE said the trial does not consider whether adding Sanofi's drug improves either length or quality of life over the long term.

Read Pharma Times article